valspodar

Phase 3Small molecule

EEastern Cooperative Oncology Group

valspodar is one of 148 small molecule programs targeting Myelodysplastic Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

147

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromeActive, not recruiting

Breast CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Acute LeukemiaActive, not recruiting

Myelodysplastic SyndromePhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Multiple MyelomaPhase 3

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Acute LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

valspodar

EEastern Cooperative Oncology Group

Phase 3

2 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

Spravato

WWim Janssens

Preclinical

2 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 10

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00006363·720 enrolled

Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00003190·640 enrolled

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00004217·55 enrolled

Breast Cancer2 trials

Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00002826·36 enrolled

Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer

Completed·—·Phase 2·NCT00002937·70 enrolled

Multiple Myeloma1 trial

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00002878

Acute Leukemia1 trial

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00002912·3 enrolled

Myelodysplastic Syndrome1 trial

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·LLeukemia Research Fund·Phase 3·NCT00005823·2,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for valspodar. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — valspodar compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for valspodar. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEastern Cooperative Oncology Group

valspodar

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Breast Cancer2 trials

Multiple Myeloma1 trial

Acute Leukemia1 trial

Myelodysplastic Syndrome1 trial

References

Drug Info

Quick Facts

Related News